Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Últimas Novedades
Lakartidningen. 2026 Mar 20:123:25150.
Autores:
Elias Björnson 1 , Jonas Brinck 2 , Emil Hagström 3 , Jan Borén 4
Circ Popul Health Outcomes. 2026 Mar;19(3):e013261. doi: 10.1161/CIRCOUTCOMES.125.013261. Epub 2026 Feb 20.
Autores:
Ashkan Abdollahi 1 2 , Aysa Ostovaneh 2 , Omar Chehab 2 , Malak Hoballah 2 , Bruna R S Matuck 2 , Colin O Wu 3 , Seamus P Whelton 4 , Bharath Ambale-Venkatesh 5 , Wendy S Post 2 , David A Bluemke 6 , Michael Y Tsai 7 , Sotirios Tsimikas 8 9 , João A C Lima 2 5
Conclusión: Elevated Lp(a) levels were independently associated with maladaptive left ventricular and left atrial remodeling in Hispanic adults over a decade, while no statistically significant relationships were observed in White, Black, and Chinese participants. This suggests a unique susceptibility of Hispanic individuals to Lp(a)-mediated cardiovascular remodeling, independent of ischemic pathways.
J Clin Lipidol. 2026 Mar;20(3):671-676. doi: 10.1016/j.jacl.2026.01.018. Epub 2026 Jan 27.
Autores:
Jadry Gruen 1 , Archna Bajaj 2
Conclusión: Ahead of results from ongoing clinical trials testing Lp(a)-targeted therapies, health systems can use QI methods to assess current Lp(a) ordering practices, identify patients who may benefit from future Lp(a)-targeted therapy, and plan for rapid expansion of Lp(a) testing.
J Clin Lipidol. 2026 Mar;20(3):600-608. doi: 10.1016/j.jacl.2026.01.015. Epub 2026 Jan 27.
Autores:
Matteo Paolucci 1 , Giacomo Urbinati 2 , Mauro Gentile 1 , Stefano Forlivesi 1 , Giorgia Arnone 1 , Ludovica Migliaccio 1 , Maria Maddalena Viola 1 , Simone Galluzzo 3 , Cristiano Fanciulli 2 , Mario Sebastiani 1 , Eric Ramazzotti 4 , Rita Mancini 4 , Luigi Simonetti 3 , Andrea Zini 5
Conclusión: Higher Lp(a) values are associated with LAA stroke, particularly ICAS. Lp(a) levels should be included in the stroke workup.
Curr Med Res Opin. 2026 Jan;42(1):19-24. doi: 10.1080/03007995.2026.2627735. Epub 2026 Feb 11.
Autores:
Andreas Tridimas 1 2 , Suha Ahmed 3
Conclusión: Routine Lp(a) testing meaningfully alters management and reveals a form of residual dyslipidaemia resistant to standard therapy. These findings, combined with recent cost-effectiveness modelling showing NHS and societal savings from one-time testing, support incorporation of Lp(a) measurement into universal cardiovascular risk assessment.
J Clin Lipidol. 2026 Mar;20(3):609-619. doi: 10.1016/j.jacl.2025.12.016. Epub 2025 Dec 23.
Autores:
Dimitrios Delialis 1 , Polyxeni Manifava 1 , Sofia-Panagiota Giannakopoulou 2 , Christina Konstantaki 1 , Stavros Athanasopoulos 1 , Georgios Zervas 1 , Panagiotis Nastatos 1 , Georgios Mavraganis 1 , Kateryna Sopova 3 , Maria-Angeliki Dimopoulou 1 , Lydia Kokkinidou 1 , Yannis Skoumas 4 , Christos Pitsavos 4 , Nikolaos Rachiotis 1 , Lasthenis Angelidakis 1 , Dimitrios Papoutsis 1 , Peggy Kostakou 1 , Elisabeth Samouilidou 5 , Achilleas A Zacharoulis 6 , Konstantinos Stellos 7 , Evangellos Liberopoulos 8 , Christina Chrysochoou 4 , Georgios Georgiopoulos 1 , Demosthenes Panagiotakos 2 , Kimon Stamatelopoulos 9
Conclusión: Elevated Lp(a) levels were observed in 8.3% of the general population cohort and up to 23.9% in participants with ASCVD from the lipid clinic cohort, highlighting a risk gradient across ASCVD categories. Incorporating Lp(a) as a risk enhancer improves ASCVD risk reclassification beyond the validated HellenicSCOREII+.
Diabetes Obes Metab. 2026 Apr;28(4):3044-3053. doi: 10.1111/dom.70491. Epub 2026 Jan 21.
Autores:
Zenglei Zhang 1 , Lin Zhao 2 , Zeyu Wang 1 , Xianliang Zhou 1 , Xianlun Li 2 , Weixian Yang 1 , Xu Meng 1
Conclusión: Elevated Lp(a) levels were associated with a higher risk of ASCVD across different glucose metabolism statuses, particularly among individuals with NGR and prediabetes, independent of baseline CRP levels.